Retraction: HMGA2 functions as a competing endogenous RNA to promote lung cancer progression.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

1. MiR-210 regulates lung adenocarcinoma by targeting HIF-1α.Heliyon · 2023
   Article
2. LINC01116 Promotes Doxorubicin Resistance in Osteosarcoma by Epigenetically Silencing miR-424-5p and Inducing Epithelial-Mesenchymal Transition.Frontiers in pharmacology · 2021
   Article
3. Hydrophobically Modified let-7b miRNA Enhances Biodistribution to NSCLC and Downregulates HMGA2 In Vivo.Molecular therapy. Nucleic acids · 2020
   Article
4. Crosstalk between let-7a-5p and BCL-xL in the Initiation of Toxic Autophagy in Lung Cancer.Molecular therapy oncolytics · 2019
   Article
5. Competing endogenous RNA (ceRNA) hypothetic model based on comprehensive analysis of long non-coding RNA expression in lung adenocarcinoma.PeerJ · 2019
   Article
6. The prognostic value of neutrophil to lymphocyte and platelet to lymphocyte ratios for patients with lung cancer.Oncology letters · 2017
   Article
7. Research Progress and Application Prospects of Long Noncoding RNAs in Gastric Neoplasms.Technology in cancer research & treatment
   Review

Corrections and comments

• Retraction of
  HMGA2 functions as a competing endogenous RNA to promote lung cancer progression.2014

Authors and funding

0 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.